Insider Selling: Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Sells $454,700.00 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Rating) CEO Helen Torley sold 10,000 shares of the company’s stock in a transaction on Tuesday, March 7th. The stock was sold at an average price of $45.47, for a total value of $454,700.00. Following the completion of the sale, the chief executive officer now owns 623,666 shares of the company’s stock, valued at $28,358,093.02. The transaction was disclosed in a filing with the SEC, which is available through this link.

Helen Torley also recently made the following trade(s):

• On Thursday, March 9th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $42.73, for a total value of $427,300.00.
• On Thursday, February 16th, Helen Torley sold 11,061 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $49.26, for a total value of $544,864.86.
• On Wednesday, February 8th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $51.36, for a total value of $513,600.00.
• On Thursday, January 19th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $52.41, for a total value of $524,100.00.
• On Thursday, December 15th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $57.37, for a total value of $573,700.00.

Halozyme Therapeutics Stock Down 2.6 %

HALO opened at $41.63 on Friday. The firm has a 50-day simple moving average of $50.30 and a two-hundred day simple moving average of $48.82. Halozyme Therapeutics, Inc. has a 52 week low of $34.00 and a 52 week high of $59.46. The company has a market capitalization of $5.64 billion, a PE ratio of 28.71, a price-to-earnings-growth ratio of 0.55 and a beta of 1.26. The company has a quick ratio of 4.88, a current ratio of 5.65 and a debt-to-equity ratio of 8.79.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in HALO. Artisan Partners Limited Partnership lifted its holdings in shares of Halozyme Therapeutics by 16.5% in the 4th quarter. Artisan Partners Limited Partnership now owns 7,140,953 shares of the biopharmaceutical company’s stock valued at $406,320,000 after acquiring an additional 1,013,061 shares during the last quarter. Norges Bank bought a new position in shares of Halozyme Therapeutics in the 4th quarter valued at about $53,957,000. Franklin Resources Inc. lifted its holdings in shares of Halozyme Therapeutics by 1,548.8% in the 2nd quarter. Franklin Resources Inc. now owns 688,216 shares of the biopharmaceutical company’s stock valued at $30,282,000 after acquiring an additional 646,475 shares during the last quarter. Two Sigma Investments LP lifted its holdings in shares of Halozyme Therapeutics by 414.4% in the 4th quarter. Two Sigma Investments LP now owns 551,074 shares of the biopharmaceutical company’s stock valued at $31,356,000 after acquiring an additional 443,935 shares during the last quarter. Finally, Driehaus Capital Management LLC lifted its holdings in shares of Halozyme Therapeutics by 51.9% in the 2nd quarter. Driehaus Capital Management LLC now owns 1,282,492 shares of the biopharmaceutical company’s stock valued at $56,430,000 after acquiring an additional 438,429 shares during the last quarter. Institutional investors own 96.32% of the company’s stock.

Analyst Upgrades and Downgrades

HALO has been the subject of a number of analyst reports. Morgan Stanley cut their price target on Halozyme Therapeutics from $65.00 to $64.00 and set an “overweight” rating for the company in a research note on Monday, March 6th. Benchmark increased their price target on Halozyme Therapeutics from $55.00 to $68.00 and gave the stock a “buy” rating in a research note on Thursday, December 8th. SVB Leerink cut their price target on Halozyme Therapeutics from $62.00 to $61.00 and set an “outperform” rating for the company in a research note on Wednesday, January 11th. Wells Fargo & Company initiated coverage on Halozyme Therapeutics in a research note on Monday, November 28th. They issued an “overweight” rating and a $65.00 price target for the company. Finally, JMP Securities reiterated a “market outperform” rating and issued a $66.00 price target (up previously from $62.00) on shares of Halozyme Therapeutics in a research note on Wednesday, February 22nd. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $62.29.

Halozyme Therapeutics Company Profile

(Get Rating)

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.